Trial Profile
A Phase I Trial of Venetoclax in Combination With BEAM Conditioning Regimen for Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan
- Indications Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 07 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Jun 2024.
- 07 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2024.